Preterm Birth and Neonatal Injuries: Importance of Interleukin-1 and Potential of Interleukin-1 Receptor Antagonists

Author(s): Mathieu Nadeau-Vallee , Dima Obari , Alexandra Beaudry-Richard , Estefania Marin Sierra , Alexandre Beaulac , Noemie Maurice , David M. Olson* , Sylvain Chemtob* .

Journal Name: Current Pharmaceutical Design

Volume 23 , Issue 40 , 2017

Abstract:

Preterm birth (PTB) is a leading cause of neonatal mortality and morbidity worldwide, and surviving infants are at increased risks of lifelong complications. PTB has been firmly linked to inflammation regardless of infection, specific aetiology or timing of birth. Deleterious inflammation is observed in maternal and fetal tissue, and correlates with the severity of perinatal complications. At present, PTB is treated with tocolytics as though it is exclusively a myometrial contractile disorder. These agents do not address underlying inflammatory processes and are thus vastly ineffective at improving neonatal outcomes. Of all inflammatory mediators, IL-1 is central to the pathophysiology of PTB and most adverse neonatal outcomes. We thus present herein a review of the various effects of IL-1 in utero, with a brief overview of its mechanism of action. We then discuss the potential of different IL-1-targeting agents based on pre-clinical testing in relevant models of PTB and neonatal inflammatory injuries.

Keywords: Interleukin-1, preterm labor, preterm birth, inflammation, neonatal injuries, neonatal mortality.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 23
ISSUE: 40
Year: 2017
Page: [6132 - 6141]
Pages: 10
DOI: 10.2174/1381612823666170825145114
Price: $58

Article Metrics

PDF: 27
EPUB: 1
PRC: 1